Focused GSK posts strong results for 2023

31 January 2024

British drugmaker GSK (LSE: GSK) has exceeded expectations in the fourth quarter of 2023, with chief executive Dame Emma Walmsley presenting an upbeat view of the company’s trajectory.

In its first annual results statement since the divestment of its consumer health unit, GSK reported total sales of £30.3 billion ($38.6 billion), an increase of 5%.

Fourth quarter sales came in at £8 billion, with adjusted profit of £8.8 billion for the year and £1.8 billion for the quarter, up 8% and 10% respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK